Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Faeth Therapeutics, Inc.NASDAQ: FTH
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses growth accelerates
Q2 FY2026 operating expenses of $18.39M rose 253.2% year over year, ahead of the +140.8% change in trailing-twelve-month operating expenses. Sequentially, it fell 51.2% from the prior quarter. Over 3 fiscal years it compounded at -22.2% a year.
Context
- Operating expenses increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +253.2% holds above the trailing-twelve-month pace of +140.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 22.29M USD
- Year-over-year change
- -28.4%
- 4-year CAGR
- -11.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.29M | -28.4% |
| FY2024 | 2024-12-31 | 31.11M | -14.7% |
| FY2023 | 2023-12-31 | 36.49M | -22.9% |
| FY2022 | 2022-12-31 | 47.31M | +28.6% |
| FY2021 | 2021-12-31 | 36.8M | — |
Operating Expenses vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's LTM Jun 2026 operating expenses of $65.86M is the 9th highest of the 10 companies compared; the peer median is $212.38M.
- Its year-over-year change of +140.8% is the highest of 10, against a peer median of +30.0%.
- Over three fiscal years its annual growth of -22.2% compares with a peer median of +30.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $385.56M | +42.1% | +38.4% | 538.2% | |
| LTM Jun 2026 | $297.23M | +30.0% | +30.7% | 174.9% | |
| LTM Jun 2026 | $251.79M | +69.1% | +76.0% | 2432.8% | |
| LTM Sep 2026 | $227.59M | +29.2% | +8.0% | — | |
| LTM Mar 2026 | $212.38M | +50.5% | +37.4% | 428.3% | |
| LTM Mar 2026 | $168.69M | +127.4% | +30.3% | 780.5% | |
| LTM Mar 2026 | $139.67M | +6.4% | -3.8% | 61.5% | |
| LTM Mar 2026 | $100.47M | -31.6% | -2.4% | 600.9% | |
| LTM Jun 2026 | $65.86M | +140.8% | -22.2% | — | |
| LTM Mar 2026 | $59.47M | -19.0% | +10.3% | — | |
| Peer median (excluding FTH) | $212.38M | +30.0% | +30.3% | 538.2% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 685K | 1.81M | 571K | 551K | 0 |
| Gross Profit | (685K) | (1.81M) | (571K) | (551K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.66M | 29.58M | 18.3M | 18.63M | 10.96M |
| Selling, General & Admin | 15.14M | 17.73M | 18.77M | 12.49M | 11.33M |
| Operating Expenses | 36.8M | 47.31M | 36.49M | 31.11M | 22.29M |
| Depreciation & Amortization | 685K | 1.81M | 3.68M | 551K | 139K |
| EBITDA | (35.44M) | (46.56M) | (33.39M) | (29.52M) | (20.91M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.48M) | (49.12M) | (37.06M) | (31.66M) | (22.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 800K | 1.78M | 3.62M | 2.55M | 1.24M |
| Interest Expense | 670K | 219K | 144K | 90K | 32K |
| Other Income / Expenses | 688K | 532K | 2.96M | 1.51M | 1.2M |
| Income Before Tax | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| EPS (Diluted) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| Weighted Avg Shares | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
| Weighted Avg Shares (Diluted) | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.